2 Healthcare Stocks to Buy Before They Get Bought Out

Abivax: lead oral candidate obefazimod is in Phase 3 for moderately-to-severely active ulcerative colitis with top-line data expected in Q2; the UC market is estimated at $8.7B in 2026 rising to $14.3B by 2035. Abivax reported €589.7M (~$697M) cash at end-Q3 2025 (funding into Q4 2027), shares are down ~10% YTD but up >1,900% over the past year amid buyout rumors involving Eli Lilly and speculative interest from AstraZeneca. Nektar: rezpegaldesleukin showed >80% of patients maintained ≥75% skin clearance at 36 weeks in Phase 2b and may offer quarterly dosing; after a $460M raise it has >$700M liquidity (funding into 2027), shares are up ~77% YTD, and analysts’ targets of $123–$130 vs. current ~$74 imply material upside; potential acquirers cited include Sanofi, AbbVie, and Amgen.

Analysis

Large acquirers with immunology and inflammation franchises are the obvious strategic winners, but the more valuable second-order beneficiaries are CDMOs and oral small‑molecule manufacturing suppliers that can scale a rapid commercial rollout; acquirers will prefer targets that minimize biologics-capex and speed-to-patient, compressing premiums for strictly injectable platforms. Market pricing already embeds a non-trivial probability of a trade sale within 12 months, which means most future upside is M&A-dependent rather than de‑risked clinical-to-commercial translation — that shifts event-risk from science to negotiation/timing and counterparty balance sheets.

Tail risks are binary and asymmetric: a negative safety or regulatory signal can cascade into 50–80% downside inside days, while positive de‑risking typically unlocks a single-digit to low‑triple digit premium in a takeover scenario but only after protracted diligence (3–12 months). Payer/pricing dynamics are an underappreciated near‑term constraint — incumbents with high per‑patient prices create a ceiling for new entrants unless superior dosing, adherence, or cost-of-goods demonstrably change the lifetime‑value math.

From a positioning perspective, the prudent approach is event‑driven sizing with explicit hedges: isolate idiosyncratic readout/M&A exposure from biotech beta by pairing with a large‑cap immunology short or using volatility‑constrained option structures. Monitor short interest and implied vol term structure — a steep front‑month IV curve signals crowded event risk and makes spreads and collars a more efficient way to take asymmetric upside exposure.

Consensus underweights execution risk post‑deal (integration, pricing pushback, EU reimbursement timelines), and may overestimate the speed at which large acquirers will convert trial readouts into offers. That gap creates two trading edges: buy protected asymmetric upside into event windows, or sell speculative post‑runup volatility after positive headlines if you expect deal timelines to be measured rather than immediate.

Key Decisions for Investors

• Long-biotech event play: Allocate 1.0–1.5% NAV to ABVX (or similar small-cap target) with a 3‑month protective put 30% OTM sized to cap downside at ~35% of position cost; take profit at 100–150% if a public bid/term sheet is announced within 12 months. Rationale: caps tail risk while preserving M&A upside; downside if trial/regulatory fails is limited to the put cost plus retained equity.
• Volatility-defined upside on NKTR: Buy a 9‑month 1x2 call spread (buy ATM, sell 2x OTM) sized to 0.75% NAV to capture binary upside while financing premium with sold calls; close or roll at 50% of max gain. R/R: limited premium outlay with ~3–5x asymmetric upside if a takeover or accelerated commercial path materializes, limited loss to premium if not.
• Idiosyncratic-vs‑beta hedge: Pair long small‑cap biotech exposure (ABVX/NKTR combined <=2% NAV) with a 1% NAV short in a large immunology name (choose AMGN or ABBV) to hedge sector‑wide risk over a 6–12 month horizon. Rationale: isolates event-specific upside while reducing market correlation; expect reduced volatility but smaller absolute returns.
• Short post‑runup volatility: If either stock gaps up >25% on positive headlines without a clear term sheet, sell a 30–60 day covered call or iron‑condor to harvest elevated IV; size to 0.5–1% NAV and be prepared to unwind into firm bids. R/R: collect premium in high‑IV window; risk is assignment on a full‑takeout — size accordingly.